In this article we investigate the relationship between executive compensation and the performance of companies of the healthcare sector in Brazil, obtained through accounting information, aiming to verify whether there is a relationship between the financial incentives offered to the management and the performance of entities in the Brazilian healthcare sector, which provided accountability to the National Regulatory Agency for Private Health Insurance and Plans (ANS) in the period from 2012 to 2016. The investigation on entities of the Brazilian healthcare sector is justified by the fact that the State provide only for 43% of the sector costs and the private initiative the remaining 57%, of which 34% through direct private costs and 23% through health insurance. We analyzed the impact of the ratios Return on Equity (ROE), Return on Assets (ROA) and on Profit of 470 companies. We also used the control variable Total Assets. We did not find statistical relation between the ROE and executive compensation. The ROA presented statistical significance, however negative, which indicated that both indicators are not used to determine the compensation policies of the sector. The Profit presented positive statistical significance, however weak, also with little impact on the compensation packages. We can conclude that the compensation packages are higher in larger companies.

Background. Captopril is an angiotensin-converting enzyme inhibitor, used as anti-hypertensive, helpful in avoiding heart failure (HF) consequences in adults. Its employment in pediatrics is conditioned to evidence-based results, since in this population, heart failure and hypertension are less common and derive mainly from anatomical malformations. Captopril behavior in children has not been formally studied through clinical trials. Aim. To evaluate the clinical outcome in a cohort of Mexican children receiving individualized doses of captopril and demonstrate its efficacy to control heart failure in pediatrics. Methods. Individualized doses of captopril were prepared and administered to 40 pediatric patients with heart failure. Captopril concentration was assayed by ultra-high-performance liquid chromatography coupled to mass detection, plasma levels were determined at day 11 and 22 of treatment. The functional class of each patient was graded by the Ross or NYHA scales. Results. The individualized doses were stable at least for four weeks. The cohort was composed by 40 patients, with age between 0.3 to 16.5 years (median 4.11 years). High variability was observed in plasma concentrations (range 5 to 326 ng/mL) according to age and doses. Clinical improvement was noteworthy, at the end of the following, only Class I and II patients were registered. In the most of patients the functional class was reduced after 22 days of treatment. Children from 0 to 3 years old had a significant clinical improvement compared to the rest of the age groups studied. Conclusions. Captopril dose adjustment was a good procedure to improve the clinical response in patients from 0 to 3 years old, but in patients older than 3 years, the therapeutic drug monitoring is necessary, because their clinical improvement was scarce.

An experimental study of electric power generation using floating physical laboratory model is presented in this paper. The main objective of this paper is produce an electric energy from a floating model consists of a horizontal hollow cylindrical pipe with a four fan blades with diameter = 10.00 cm, hanging over a single axe which connect with a small gear whose installed with a simple dynamo producing electricity through a conveyor, this system was placed in a floating foundation, so an electric power can be generated from the movement of these blades by the action of wave energy. Testing different water depths, wave heights, lengths and periods to produce high electrical power or to charging batteries with different sizes, the experiments were done in the laboratory of Hydraulics, Civil Engineering Department, Shorouk City, Higher Institute of Engineering.

This article examines the consequences of the Brexit for the general budget of the European Union. Wat are the possibilities for compensating the loss of the British contributions to the EU budget ?